Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Sanara MedTech (SMTI) over the last 15 years, with Q3 2025 value amounting to $2.2 million.

  • Sanara MedTech's Cash from Operations rose 614.36% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 30913.83%. This contributed to the annual value of -$23784.0 for FY2024, which is 9926.72% up from last year.
  • Latest data reveals that Sanara MedTech reported Cash from Operations of $2.2 million as of Q3 2025, which was up 614.36% from $2.7 million recorded in Q2 2025.
  • Sanara MedTech's 5-year Cash from Operations high stood at $2.7 million for Q2 2025, and its period low was -$2.1 million during Q1 2022.
  • For the 5-year period, Sanara MedTech's Cash from Operations averaged around -$568272.0, with its median value being -$1.3 million (2021).
  • Per our database at Business Quant, Sanara MedTech's Cash from Operations crashed by 24530.3% in 2022 and then soared by 28867.87% in 2025.
  • Quarter analysis of 5 years shows Sanara MedTech's Cash from Operations stood at -$1.8 million in 2021, then soared by 63.85% to -$645016.0 in 2022, then crashed by 31.55% to -$848532.0 in 2023, then surged by 209.84% to $932047.0 in 2024, then soared by 133.51% to $2.2 million in 2025.
  • Its Cash from Operations stands at $2.2 million for Q3 2025, versus $2.7 million for Q2 2025 and -$2.0 million for Q1 2025.